Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
89 hedge funds and large institutions have $1.32B invested in Verona Pharma in 2022 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 9 closing their positions.
374% more call options, than puts
Call options by funds: $29.8M | Put options by funds: $6.3M
256% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 9
149% more capital invested
Capital invested by funds: $529M → $1.32B (+$787M)
129% more funds holding in top 10
Funds holding in top 10: 7 → 16 (+9)
31% more funds holding
Funds holding: 68 → 89 (+21)
8% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 24
13.44% less ownership
Funds ownership: 85.46% → 72.02% (-13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.4M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$15.2M |
| 3 |
Jennison Associates
New York
|
+$13.7M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$9.54M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$4.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$14.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.26M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.83M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.66M |
VRNA Hedge Fund Activity: Q4 2022 in Review
89 of the 6,240 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q4 2022, worth a combined $1.32B — up 149% from $529M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new VRNA positions and 9 closed out — a net gain of 23 holders — while 26 added to existing stakes and 24 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $23.4M. The largest seller was OrbiMed, cutting an estimated $14.9M.
- 89 institutional investors held Verona Pharma (VRNA) as of Q4 2022, up from 68 in Q3 2022.
- Funds reported $1.32B of Verona Pharma stock for Q4 2022, up 149% quarter-over-quarter.
- 32 funds opened new Verona Pharma positions in Q4 2022 and 9 closed out, a net change of +23 holders.
- The largest Verona Pharma buyer in Q4 2022 was Fidelity Investments, an estimated $23.4M added.
- The largest Verona Pharma seller in Q4 2022 was OrbiMed, an estimated $14.9M sold.
Based on aggregated 13F filings for Q4 2022.